Edwyn
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3,197 | $3,578 | $4,223 | $4,685 | $5,146 |
| Gross Profit | $1,839 | $2,024 | $2,356 | $2,655 | $3,055 |
| Operating Income | $904 | $1,000 | $1,132 | $1,320 | $1,685 |
| Net Income | $475 | $779 | $898 | $1,021 | $1,401 |
Over the five-year period from 2021 to 2025, ResMed Inc. demonstrated steady growth across key income statement metrics. Revenue increased from approximately $3.20 billion in 2021 to about $5.15 billion in 2025, representing an overall growth of roughly 61%. Gross profit followed a similar positive trend, rising from $1.84 billion to $3.05 billion, with margins appearing to remain healthy as the increase in gross profit parallels revenue growth. Operating income experienced consistent gains—from $903.7 million in 2021 to $1,685.4 million in 2025—including a notable jump of nearly 28% from 2024 to 2025, suggesting operational efficiencies or expansion in high-margin segments. Net income also advanced steadily, moving from $474.5 million to $1,400.7 million, reflecting both the company’s expanding operational scale and effective cost management. The year-over-year swings, particularly the significant increase in net income of around 64% from 2021 to 2022 and the over 20% rise in operating income from 2024 to 2025, indicate periods of accelerated performance that could be driven by improved product uptake or operational improvements. Within the context of the medical device industry—where ResMed is a key player in respiratory and sleep care—the consistent upward trajectory of these financial metrics points to robust market demand and effective capitalizing on demographic trends such as aging populations and increased awareness of respiratory health. Overall, based on the provided figures, ResMed Inc. appears to be in sound financial health with sustainable growth, marked by improving profitability and solid revenue expansion that align well with its industry profile.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.